Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cipepofol for general anesthesia in pediatric patients
NCT06391931Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cipepofol in general anesthesia (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Success rate of anesthesia. Started Apr 2024; status: completed.
02
Drugs
cipepofol
03
Conditions
general anesthesia
Beyond the preview
Go deeper on NCT06391931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391931.